瑞格非尼治疗转移复发性结直肠癌的研究进展

Progression of regorafenib on metastatic colorectal cancer

目前,针对特异性分子靶点的靶向药物治疗已成为转移复发性结直肠癌(mCRC)治疗的新方向。2012年瑞格非尼被美国FDA批准用于mCRC患者,瑞格非尼是一种新型小分子多激酶抑制剂,能阻断多种促进肿瘤生长的激酶。多项临床研究结果显示瑞格非尼能显著延长mCRC患者的生存期。本文结合国内外最新研究报道,对瑞格非尼治疗mCRC的研究进展作一综述。

Lacking of available treatments for metastatic colorectal cancer （mCRC） patients progressed with standard prior therapies, it has lead to the research into new active molecules. Regorafenib is an oral small-molecule multi kinase inhibitor, targeting both tumor cell proliferation and vasculature, with potent inhibitory activity against vascular endothelial growth factor receptors, platelet-derived growth factor receptor, fibroblast growth factor receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. The an- titumor activity of regorafenib has been confirmed in vitro and in vivo study. The results of several clinical trials reveal that the benefit of regorafenib on the overall survival of mCRC patients. In this paper, the progression of regorafenib on mCRC are summarized.